Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. (Nasdaq: EDIT) is a clinical-stage gene editing company that regularly issues news and updates about its in vivo CRISPR-based pipeline. Company announcements emphasize the development of transformative in vivo medicines using CRISPR/Cas12a and CRISPR/Cas9 systems, proprietary targeted lipid nanoparticle delivery, and a differentiated gene upregulation strategy applied to serious diseases.
News about Editas Medicine frequently covers progress with its lead in vivo development candidate, EDIT-401, an LDLR-targeted gene editing medicine designed to treat hyperlipidemia by increasing LDL receptor expression and reducing LDL cholesterol (LDL-C) levels. Recent releases have described preclinical proof-of-concept data in non-human primates and mice, showing approximately 90% or greater reductions in LDL-C after a single dose, as well as presentations at major scientific meetings such as the European Society of Gene and Cell Therapy Congress and the American Heart Association Scientific Sessions.
Investors and followers of EDIT can also expect updates on Editas’ in vivo hematopoietic stem cell program for sickle cell disease and beta thalassemia, including data on HBG1/2 promoter editing, fetal hemoglobin upregulation, and targeted lipid nanoparticle delivery in humanized mice and non-human primates. Additional news items highlight in vivo proof-of-concept for undisclosed liver targets, conference presentations at ASGCT, EHA, and TIDES, and participation in healthcare and investor conferences.
Financial news from Editas Medicine includes quarterly results, collaboration milestones such as the CD19 HD allogeneic CAR T program with Bristol Myers Squibb, and updates on cash runway supported by cash, marketable securities, at-the-market equity proceeds, and payments under its license agreement with Vertex Pharmaceuticals. This news page helps readers follow how scientific data, regulatory plans, collaborations, and financial developments shape the EDIT investment story over time.
Editas Medicine (Nasdaq: EDIT) announced that the FDA has granted Orphan Drug Designation to its investigational gene editing medicine EDIT-301 for treating sickle cell disease. This designation recognizes the urgent need for new therapies for a condition affecting around 100,000 individuals in the U.S.
The company aims to dose 20 patients in the ongoing RUBY trial by year-end, with clinical data updates expected mid-2023 and by year-end. EDIT-301 is also under investigation for treating transfusion-dependent beta thalassemia. The Orphan Drug Designation offers various incentives, including tax credits and potential marketing exclusivity upon FDA approval.
President and CEO Gilmore O’Neill emphasized the potential of EDIT-301 to provide significant clinical benefits to patients.
Editas Medicine (Nasdaq: EDIT) announced the appointment of Emma Reeve as Chair of the Board, effective at the next annual stockholder meeting on June 1, 2023. Reeve replaces James C. Mullen, who is stepping down. Additionally, Elliott Levy, M.D., joins the Board as an Independent Director. Reeve, who has been on the Board since September 2021, brings over 25 years of biopharmaceutical experience. Her leadership in overseeing the recent strategic changes at Editas positions her well for this role. Dr. Levy, an accomplished biopharmaceutical executive with extensive R&D experience, is expected to enhance the company’s drug development efforts. Dr. O’Neill, the CEO, expressed confidence in the new leadership while thanking Mullen for his contributions over the last five years.
Editas Medicine, Inc. (Nasdaq: EDIT) announced the appointment of Linea Aspesi as Executive Vice President and Chief People Officer, effective March 8, 2023. Aspesi, who has over 25 years of experience, will lead the company’s human resources and people strategy, aligning talent development with Editas' mission to transition into a commercial-stage organization. Her previous role was at Forma Therapeutics, where she played a key role in the $1B acquisition by Novo Nordisk. The leadership change is expected to enhance Editas' growth prospects and cultural transformation, critical for its strategy in delivering genomic medicines.
Editas Medicine, Inc. (Nasdaq: EDIT) announced key updates from its clinical trials and financial results for Q4 and full year 2022. The company has begun parallel dosing in the EDIT-301 RUBY trial for Sickle Cell Disease (SCD), aiming to dose 20 patients by year-end. They are also set to dose the first patient in the EDITHAL trial for Transfusion-dependent Beta Thalassemia (TDT) in Q1 2023. Financially, net loss for Q4 2022 reached $60.7 million, increasing from $41.4 million in Q4 2021. Overall, 2022 net loss totaled $220.4 million. Cash reserves stood at $437.4 million, projected to fund operations into 2025.
Editas Medicine, a clinical-stage genome editing company, will host a conference call and webcast on February 22, 2023, at 8:00 a.m. ET, to discuss its fourth quarter and full year 2022 results along with a corporate update. U.S. callers can join by dialing 877-407-0989 and international callers should dial 201-389-0921. The call can also be accessed via the Editas Medicine website in the 'Investors' section, with a replay available about an hour after the call ends.
Editas focuses on developing transformative genomic medicines utilizing CRISPR technologies, and holds exclusive licenses for crucial patents in human medicine.
Editas Medicine (Nasdaq: EDIT) has entered a definitive agreement with Shoreline Biosciences to license its proprietary SLEEK gene editing technology and AsCas12a enzyme. Shoreline will acquire Editas' preclinical iNK cell franchise, including EDIT-202, aimed at solid tumors. The agreement entails an upfront payment, along with future development milestones and royalty payments for these assets. This move aligns with Editas' strategic emphasis on in vivo gene editing, allowing it to consolidate resources for advancing clinical trials. Shoreline aims to leverage these technologies for next-generation immunotherapies against cancer.
Editas Medicine (Nasdaq: EDIT) announced a strategic update focusing on hemoglobinopathies and in vivo gene editing. The company will discontinue investments in inherited retinal diseases and preclinical iNK programs, resulting in a workforce reduction of approximately 20%. This move aims to extend the cash runway into 2025 and prioritize resources towards EDIT-301, its lead program for severe sickle cell disease. Additionally, Chief Scientific Officer Mark S. Shearman will step down on March 31, 2023. Editas plans to present further details at the J.P. Morgan Healthcare Conference on January 10, 2023.
Editas Medicine, a clinical stage genome editing company, will have its President and CEO, Gilmore O’Neill, present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA. The presentation will be accessible via live webcast on the company’s website, with an archived replay available for 30 days post-event. Editas Medicine focuses on developing transformative genomic medicines using CRISPR technology to treat serious diseases globally, holding exclusive licenses for key patents.
Editas Medicine announced positive initial clinical data from the first two patients treated with EDIT-301 for severe sickle cell disease (SCD) in the Phase 1/2 RUBY trial. Both patients demonstrated successful engraftment without vaso-occlusive events during follow-up. The first patient achieved a total hemoglobin level of 16.4 g/dL and 45.4% fetal hemoglobin five months after treatment. EDIT-301 showed a favorable safety profile, consistent with myeloablative conditioning. The company plans to present further updates in mid-2023.
Editas Medicine (Nasdaq: EDIT) will host a webinar on December 6 at 8:00 a.m. ET to present initial clinical data from the Phase 1/2 RUBY trial of EDIT-301, aimed at treating severe sickle cell disease. The data will cover safety results from the first two patients and efficacy findings from the first patient treated. Sickle cell disease affects approximately 100,000 individuals in the U.S., causing severe health issues. EDIT-301 is an experimental therapy designed to enhance fetal hemoglobin production, potentially offering durable treatment benefits.